News
Aurabeat, USFDA Approved Anti-Covid Class 2 Medical Device for SARS-COV-2 Disinfection Launched in India
Aurabeat, USFDA approved anti-Covid Class 2 medical device for SARS-COV-2 disinfection was launched in India. Hong Kong-based Aurabeat has developed the patented AG+ five-stage...
Press Releases
Indian Immunologicals hands over first batch of COVAXIN Drug Substance to Bharat Biotech in Record Time
In order to augment the Covid 19 vaccine production capacity in our country so that a significant percentage of the population can get vaccinated...
News
Bora Pharmaceuticals Appoints Senior Vice President to Strengthen Global Sales and Marketing Function
Bora Pharmaceuticals, a leading full-service contract development and manufacturing organization (CDMO), has appointed Sally Langa as its new Global SVP Sales and Marketing to...
Clinical Trials
Valneva Initiates Further Phase 3 Clinical Trial for its COVID-19 Vaccine Candidate
Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, announced...
News
Australian Therapeutic Goods Administration Grants Provisional Registration for Moderna’s COVID-19 Vaccine
Moderna, Inc, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the Therapeutic Goods Administration (TGA) has granted provisional registration to...
Press Releases
Moderna and Canada Announce Collaboration to Bring mRNA Manufacturing to Canada
Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced a Memorandum of Understanding (MoU) with the government of Canada to...
Clinical Trials
AzurRx BioPharma Adds New Clinical Trial Sites in Ukraine for Phase 2 RESERVOIR of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
AzurRx BioPharma, Inc., a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal (GI) diseases, announced the completion of site initiation...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read